Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 745 of 6351
-
Eye implant could replace monthly shots for blinding disease
Disease control OngoingThis study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese pa…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo aims to ease heart failure symptoms and prevent hospital stays
Disease control Recruiting nowThis study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in co…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can one targeted drug still work after another fails? new trial aims to find out
Disease control Recruiting nowThe purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+…
Phase 2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare cancers: experimental drug ADCT-701 enters human trials
Disease control Recruiting nowBackground: Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed. Objective: To…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could an antidepressant help curb meth use in people treated for opioid addiction?
Disease control Recruiting nowThis project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to signifi…
Phase 2 • Sponsor: Washington State University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Storytelling therapy shows promise for refugee teens' mental health
Symptom relief CompletedThis study evaluated whether a culturally adapted 10-week narrative therapy program could reduce anxiety and depression symptoms among middle school students living in refugee camps in Northern Palestine. Adolescents aged 12-15 years from UNRWA-operated schools with moderate-to-s…
Sponsor: Nablus University for Vocational and Technical Education • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Could gentle radio waves ease menopause symptoms?
Symptom relief CompletedThis study will test if non-ablative monopolar radiofrequency can help improve vaginal tissue and reduce symptoms of Genitourinary Syndrome of Menopause (GSM) in postmenopausal women. The study is a randomized, sham-controlled clinical trial in which participants and outcome asse…
Sponsor: University of Castilla-La Mancha • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Spinal zaps may reboot arm movement after paralysis or stroke
Disease control Recruiting nowTranscutaneous electrical stimulation (tcES) of the spinal cord has shown great promise in restoring upper extremity function after spinal cord injury (SCI). More recently, the use of invasive, epidural electrical stimulation of the spinal cord has also demonstrated promise in re…
Phase 2/3 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Blood test may spot kidney transplant rejection without a biopsy
Diagnosis OngoingThis is a multinational, multi-center, observational cohort study. Kidney allograft rejection is poorly detected by standard-of-care biomarkers. Although dd-cfDNA has been associated with improved rejection detection when added to standard-of-care biomarkers and clinical paramet…
Sponsor: Paris Translational Research Center for Organ Transplantation • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial
Disease control Recruiting nowThis is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian can…
Phase 2 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart showdown: stents vs. bypass surgery in diabetes patients
Disease control Recruiting nowThe objective of this randomized study was to compare outcomes of imaging-and physiology-guided state-of-the-art percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) in patients with diabetes and three-vessel CAD (not involving left main).
Sponsor: Duk-Woo Park, MD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New bispecific antibody YKST02 enters human trials for Hard-to-Treat myeloma
Disease control Recruiting nowThis study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
Phase 1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New triple therapy shows promise in shrinking advanced stomach tumors before surgery
Disease control Recruiting nowThis Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III …
Phase 2 • Sponsor: Zekuan Xu • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Single shot could lift postpartum depression, early trial hints
Symptom relief CompletedThe purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Phase 2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to stop aggressive lymphoma relapse
Disease control Recruiting nowThis study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whic…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for eczema sufferers: drug switch trial launches
Disease control Recruiting nowAtopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill aims to slash severe hypoglycemia in type 1 diabetes
Disease control OngoingThis is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Phase 3 • Sponsor: vTv Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New shot could tame tough eczema in large trial
Disease control CompletedThis trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
Phase 3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy targets tough lymphoma in early trial
Disease control Recruiting nowThis phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a…
Phase 1/2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can magnetic pulses rebuild hamstring strength after ACL surgery?
Symptom relief Recruiting nowAnterior cruciate ligament (ACL) tear is common. It accounts for over 50% of all knee injuries. Anterior cruciate ligament reconstruction (ACLR) with hamstring tendon (HT) autograft is the common graft choice for ACLR. However, the outcomes of donor site healing and recovery of m…
Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC